TY - JOUR
T1 - A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells
T2 - A new tool to decipher their chemoresistance and self-renewal mechanisms
AU - Griessinger, Emmanuel
AU - Anjos-Afonso, Fernando
AU - Pizzitola, Irene
AU - Rouault-Pierre, Kevin
AU - Vargaftig, Jacques
AU - Taussig, David
AU - Gribben, John
AU - Lassailly, François
AU - Bonnet, Dominique
PY - 2014
Y1 - 2014
N2 - Acute myeloid leukemia-initiating cells (LICs) are responsible for the emergence of leukemia and relapse after chemotherapy. Despite their identification more than 15 years ago, our understanding of the mechanisms responsible for their self-renewal activity and their chemoresistance remains poor. The slow progress in this area is partly due to the difficulty of studying these cells ex vivo. Indeed, current studies are reliant on xenotransplantation assays in immunodeficient mice. In this paper, we report that by modeling key elements of the bone marrow niche using different stromal feeder layers and hypoxic culture conditions, we can maintain LICs over at least 3 weeks and support their self-renewal properties demonstrated through primary and secondary successful xenograft. We provide a proof of principle that this niche-like culture system can be used to study LIC chemoresistance following in vitro cytarabine treatment similarly to the xenograft chemotherapy model. We found that although LICs are believed to be more chemoresistant than non-LICs, functionally defined LICs are not enriched after cytarabine treatment, and heterogeneity in their resistance to treatment can be seen between patients and even within the same patient. We present a culture system that can be used as an in vitro surrogate for xenotransplantation and that has the potential to dramatically increase the throughput of the investigation of LICs. This would further provide the means by which to identify and target the functionality of the different signaling pathways involved in the maintenance and resistance of LICs to improve acute myeloid leukemia treatments.
AB - Acute myeloid leukemia-initiating cells (LICs) are responsible for the emergence of leukemia and relapse after chemotherapy. Despite their identification more than 15 years ago, our understanding of the mechanisms responsible for their self-renewal activity and their chemoresistance remains poor. The slow progress in this area is partly due to the difficulty of studying these cells ex vivo. Indeed, current studies are reliant on xenotransplantation assays in immunodeficient mice. In this paper, we report that by modeling key elements of the bone marrow niche using different stromal feeder layers and hypoxic culture conditions, we can maintain LICs over at least 3 weeks and support their self-renewal properties demonstrated through primary and secondary successful xenograft. We provide a proof of principle that this niche-like culture system can be used to study LIC chemoresistance following in vitro cytarabine treatment similarly to the xenograft chemotherapy model. We found that although LICs are believed to be more chemoresistant than non-LICs, functionally defined LICs are not enriched after cytarabine treatment, and heterogeneity in their resistance to treatment can be seen between patients and even within the same patient. We present a culture system that can be used as an in vitro surrogate for xenotransplantation and that has the potential to dramatically increase the throughput of the investigation of LICs. This would further provide the means by which to identify and target the functionality of the different signaling pathways involved in the maintenance and resistance of LICs to improve acute myeloid leukemia treatments.
KW - Acute myeloid leukemia
KW - Leukemia initiating cells
KW - Leukemic long-term culture initiating cell
KW - Xenograft
UR - http://www.scopus.com/inward/record.url?scp=84897535410&partnerID=8YFLogxK
U2 - 10.5966/sctm.2013-0166
DO - 10.5966/sctm.2013-0166
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 24493855
AN - SCOPUS:84897535410
VL - 3
SP - 520
EP - 529
JO - Stem cells translational medicine
JF - Stem cells translational medicine
SN - 2157-6564
IS - 4
ER -